A large number of treatments administered in hematologic malignancy patients, including chemotherapy agents, are metabolized through the cytochrome P-450 (CYP) pathway, with potential important interactions with agents, such as voriconazole and posaconazole, both strong inhibitors of CYP3A4. This evidence concerns the gene CYP3A4 and hematologic disorder.